Incidental combined hepatocellular-cholangiocarcinoma in liver transplant patients: Does it have a worse prognosis?
Combined hepatocellular-cholangiocarcinoma
incidental
liver
mixed tumor
transplantation
Journal
Hepatology forum
ISSN: 2757-7392
Titre abrégé: Hepatol Forum
Pays: Turkey
ID NLM: 9918351171306676
Informations de publication
Date de publication:
2023
2023
Historique:
received:
06
10
2022
revised:
17
04
2023
accepted:
08
05
2023
medline:
12
10
2023
pubmed:
12
10
2023
entrez:
12
10
2023
Statut:
epublish
Résumé
Combined hepatocellular-cholangiocarcinoma (CHC) requires attention clinically and pathologically after liver transplantation (LT) because of its unique biology, difficulties in diagnosis, and being rare. We aimed to present our single-center experience for this incidental combined tumor. It is aimed to present our single-center experience for this incidental combined tumor. Seventeen patients with CHC were included in the study. There were 260 hepatocellular carcinoma (HCC) patients determined as the control group. Patients were evaluated for demographic, etiological, pathological features, and survival. Macrovascular and microvascular invasion levels were significantly higher in the CHC group (p<0.05). P53, CK19, and CK7 levels were significantly higher in the CHC group (p<0.05). Hepatocyte-specific antigen level was significantly higher in the HCC group. The mean overall survival was significantly higher in the HCC group (p<0.05). Even though CHC is a rare liver tumor, it has features that need to be clarified regarding both survival and tumor biology. İnvestigating prognostic factors, especially in terms of survival and recurrence, will be very beneficial to identify candidates who will benefit from LT and be included in the indications for LT for CHC. This study evaluated the outcomes of patients showing combined HCC-intrahepatic cholangiocarcinoma in explant pathology.
Sections du résumé
Background and Aim
UNASSIGNED
Combined hepatocellular-cholangiocarcinoma (CHC) requires attention clinically and pathologically after liver transplantation (LT) because of its unique biology, difficulties in diagnosis, and being rare. We aimed to present our single-center experience for this incidental combined tumor. It is aimed to present our single-center experience for this incidental combined tumor.
Materials and Methods
UNASSIGNED
Seventeen patients with CHC were included in the study. There were 260 hepatocellular carcinoma (HCC) patients determined as the control group. Patients were evaluated for demographic, etiological, pathological features, and survival.
Results
UNASSIGNED
Macrovascular and microvascular invasion levels were significantly higher in the CHC group (p<0.05). P53, CK19, and CK7 levels were significantly higher in the CHC group (p<0.05). Hepatocyte-specific antigen level was significantly higher in the HCC group. The mean overall survival was significantly higher in the HCC group (p<0.05).
Conclusion
UNASSIGNED
Even though CHC is a rare liver tumor, it has features that need to be clarified regarding both survival and tumor biology. İnvestigating prognostic factors, especially in terms of survival and recurrence, will be very beneficial to identify candidates who will benefit from LT and be included in the indications for LT for CHC. This study evaluated the outcomes of patients showing combined HCC-intrahepatic cholangiocarcinoma in explant pathology.
Identifiants
pubmed: 37822306
doi: 10.14744/hf.2022.2022.0037
pii: hf-4-097
pmc: PMC10564256
doi:
Types de publication
Journal Article
Langues
eng
Pagination
97-102Informations de copyright
© Copyright 2023 by Hepatology Forum.
Déclaration de conflit d'intérêts
The authors have no conflict of interest to declare.
Références
Jpn J Radiol. 2020 Aug;38(8):697-718
pubmed: 32246350
J Surg Oncol. 2013 May;107(6):608-12
pubmed: 23386397
Medicine (Baltimore). 2019 Sep;98(38):e17102
pubmed: 31567946
Surg Today. 2006;36(10):892-7
pubmed: 16998683
Liver Transpl. 2011 Aug;17(8):934-42
pubmed: 21438129
Jpn J Clin Oncol. 2003 Jun;33(6):283-7
pubmed: 12913082
Chin J Cancer. 2016 Aug 24;35(1):82
pubmed: 27552844
Am J Surg. 2005 Jan;189(1):120-5
pubmed: 15701504
BMC Cancer. 2019 Feb 27;19(1):178
pubmed: 30813928
Chin Clin Oncol. 2016 Oct;5(5):66
pubmed: 27829279
Int J Clin Pract. 2008 Aug;62(8):1271-8
pubmed: 18284443
J Hepatol. 2014 Jun;60(6):1268-89
pubmed: 24681130
Histopathology. 2017 Feb;70(3):423-434
pubmed: 27634656
Cancer. 2002 Apr 1;94(7):2040-6
pubmed: 11932907
Yonsei Med J. 2011 Sep;52(5):753-60
pubmed: 21786439
J Gastroenterol Hepatol. 2019 Jun;34(6):1074-1080
pubmed: 30462849
Ann Surg. 2008 Jul;248(1):84-96
pubmed: 18580211
Semin Liver Dis. 2020 May;40(2):124-130
pubmed: 31887773
World J Hepatol. 2017 Feb 28;9(6):300-309
pubmed: 28293379
Int J Surg. 2019 Dec;72:156-165
pubmed: 31704426
Liver Int. 2006 Sep;26(7):781-8
pubmed: 16911459
Transplantation. 2020 Jun;104(6):1125-1130
pubmed: 32217937
Liver Transpl. 2018 May;24(5):634-644
pubmed: 29514406